PULSE BIOSCIENCES, INC.
Business
Pulse Biosciences is a medical device company developing proprietary Nano-pulse Stimulation (NPS) and nanosecond pulsed-field ablation (nsPFA) technology to nonthermally ablate targeted cells. The company manufactures the nPulse Console platform and disposable applicators for soft tissue and cardiac ablation, with FDA 510(k) clearance for the Vybrance Percutaneous Electrode System for benign thyroid nodule ablation and ongoing clinical development of cardiac surgical and catheter-based ablation systems for atrial fibrillation treatment. Pulse markets its devices through direct clinical engagement and pilot programs to cardiac surgeons, electrophysiologists, and soft tissue specialists in the United States and Europe.
Summary from 10-K filed 2026-02-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Product revenue | 350,000 | 0 | 0 | 700,000 | 1 | |
| Cost of product revenue | 539,000 | 0 | 0 | 12 | 2 | |
| Research and development | 45 | 32 | 28 | 21 | 29 | |
| Selling, general and administrative | 32 | 24 | — | — | — | |
| Total cost and expenses | 77 | 56 | 44 | 59 | 64 | |
| Loss from operations | −77 | −56 | −44 | −58 | −63 | |
| Interest income | 4 | 3 | 1 | −448,000 | −646,000 | |
| Other expense | −52,000 | −18,000 | — | — | — | |
| Total other income | 4 | 3 | 1 | −448,000 | −646,000 | |
| Net loss | −73 | −54 | −42 | −59 | −64 | |
| Comprehensive loss | −73 | −54 | −42 | −59 | −64 | |
| Net loss per share, basic and diluted (in dollars per share) | −1.08 | −0.92 | −0.85 | −1.72 | −2.28 | |
| Weighted average common shares outstanding, basic and diluted (in shares) | 67 | 58 | 50 | 34 | 28 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 81 | 118 | 44 | 61 | 29 | |
| Accounts receivable | 274,000 | 0 | — | 0 | 61,000 | |
| Inventory | 136,000 | 0 | — | 0 | 6 | |
| Prepaid expenses and other current assets | 2 | 1 | 963,000 | 1 | 2 | |
| Total current assets | 83 | 119 | 45 | 62 | 37 | |
| Property and equipment, net | 1 | 1 | 2 | 2 | 2 | |
| Intangible assets, net | 575,000 | 1 | 2 | 3 | 3 | |
| Goodwill | 3 | 3 | 3 | 3 | 3 | |
| Right-of-use assets | 6 | 7 | 7 | 8 | 9 | |
| Other assets | 691,000 | 677,000 | 365,000 | 365,000 | 365,000 | |
| Total assets | 95 | 132 | 59 | 78 | 54 | |
| Accounts payable | 3 | 2 | 2 | 2 | 3 | |
| Accrued liabilities | 4 | 7 | 4 | 3 | 4 | |
| Lease liability, current | 2 | 1 | 1 | 896,000 | 774,000 | |
| Total current liabilities | 8 | 10 | 7 | 6 | 9 | |
| Lease liability, less current portion | 6 | 8 | 8 | 9 | 10 | |
| Total liabilities | 14 | 18 | 15 | 80 | 19 | |
| Preferred stock, $0.001 par value; authorized 50,000,000 shares; no shares issued and outstanding | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.001 par value; authorized 500,000,000 shares; issued and outstanding 67,839,689 shares and 65,925,503 shares as of December 31, 2025 and 2024, respectively | 68,000 | 66,000 | 55,000 | 37,000 | 29,000 | |
| Additional paid-in capital | 544 | 505 | 381 | 292 | 272 | |
| Accumulated deficit | −463 | −391 | −337 | −295 | −236 | |
| Total stockholders equity | 81 | 115 | 44 | −2 | 36 | |
| Total liabilities and stockholders equity | 95 | 132 | 59 | 78 | 54 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 400,000 | 500,000 | 500,000 | 700,000 | 500,000 | |
| Amortization of intangible assets | 665,000 | 666,000 | 665,000 | 665,000 | 666,000 | |
| Stock-based compensation | 21 | 14 | 7 | 5 | 15 | |
| Non-cash lease expense | 1 | 923,000 | — | — | — | |
| Loss on disposal of fixed assets | 0 | 6,000 | 13,000 | 185,000 | 0 | |
| Accounts receivable | −274,000 | 0 | 0 | 61,000 | −61,000 | |
| Inventory | −136,000 | 0 | 0 | −3 | −6 | |
| Prepaid expenses and other current assets | −912,000 | −355,000 | −65,000 | 1 | −1 | |
| Other non-current assets | −14,000 | −31,000 | 0 | 0 | 0 | |
| Accounts payable | 1 | −201,000 | 263,000 | −1 | 1 | |
| Accrued liabilities | −3 | 3 | 1 | −2 | −937,000 | |
| Lease liabilities, net | −1 | −1 | −896,000 | −774,000 | −542,000 | |
| Net cash used in operating activities | −54 | −36 | −33 | −47 | −54 | |
| Purchases of property and equipment | −315,000 | −125,000 | −121,000 | −401,000 | −437,000 | |
| Purchases of intangible assets | −20,000 | 0 | — | — | — | |
| Net cash used in investing activities | −335,000 | −125,000 | −121,000 | −401,000 | 8 | |
| Proceeds from issuance of common stock under employee stock purchase plan | 586,000 | 478,000 | 395,000 | 486,000 | 810,000 | |
| Proceeds from exercises of warrants, net of issuance costs | 14 | 49 | 15 | 26,000 | 4 | |
| Proceeds from exercises of stock options | 2 | 871,000 | 1 | 0 | 786,000 | |
| Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs | 0 | 60 | 0 | — | — | |
| Payment of deferred issuance costs in relation to at-the-market equity offering program | 0 | −281,000 | 0 | — | — | |
| Net cash provided by financing activities | 17 | 110 | 16 | 80 | 63 | |
| Net (decrease) increase in cash and cash equivalents | −37 | 74 | −17 | 33 | 16 | |
| Proceeds from exercise of warrants and stock options not yet received | 45,000 | 92,000 | — | 0 | 0 | |
| Unpaid warrant issuance costs | 2,000 | 13,000 | — | — | — | |
| Unpaid amounts related to purchase of equipment | 8,000 | 26,000 | — | −27,000 | −27,000 | |
| Right-of-use asset obtained in exchange for lease liability | 0 | 830,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is PULSE BIOSCIENCES, INC.'s CIK number?
PULSE BIOSCIENCES, INC.'s SEC CIK number is 0001625101 (1625101). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find PULSE BIOSCIENCES, INC.'s SEC filings?
All of PULSE BIOSCIENCES, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did PULSE BIOSCIENCES, INC. last report earnings?
PULSE BIOSCIENCES, INC. (PLSE) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-014547). This is PULSE BIOSCIENCES, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is PULSE BIOSCIENCES, INC.'s most recent earnings 8-K?
PULSE BIOSCIENCES, INC.'s latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001437749-26-014547. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View PULSE BIOSCIENCES, INC.'s latest earnings 8-K →
Look up any company's CIK number →